[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancer-stage-ii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancer-stage-ii":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,80,108,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643840","early-phase-1-nebulized-aer101-in-pre-op-nsclc-100643840",false,"NCT07631299","Nebulized AER101 in Pre-op NSCLC","Nebulized AER101 to Inhibit Glycolysis for Pre-Operative Non-small Cell Lung Cancer (NSCLC)","AER101","Inclusion Criteria:\n\n* 18 years or older\n* Agree to sign consent and follow study requirements\n* Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma\n* Primary patients prior to resection\n* Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to)\n* Baseline PET\u002FCT imaging performed at Stephenson Cancer Center available and performed within previous 30 days\n\nExclusion Criteria:\n\n* Recurrent tumor(s)\n* Nodal or metastatic tumor (multiple lung tumors are acceptable)\n* Pregnant patients\n* Patients unable to provide informed consent\n* Prisoners","ALL","18 Years","100 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors.\n\nParticipants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.",[27,28],"Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II",[30,31],"Non-small Cell Lung Cancer","Nebulization","NOT_YET_RECRUITING","2026-06-03",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":21},"2026-06",{"date":40,"type":21},"2027-06",{"name":42,"class":43},"University of Oklahoma","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100617831","phase-2-a-study-of-bio-300-and-thoracic-radiation-therapy-in-people-with-non-small-cell-lung-cancer-and-interstitial-lung-disease-100617831","NCT07323732","A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease","A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)","Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Patient age ≥ 18 at time of consent\n* Stage I - II NSCLC (as per the American Joint Commission on Cancer (AJCC) 8th edition)\n\n  ° Pathologically proven diagnosis of cancer is strongly recommended but is not required if the risk of biopsy is unacceptable. If pathological evidence is not available, there must be clinical evidence for NSCLC and multidisciplinary consensus for treatment.\n* Interstitial Lung Disease diagnosis (one of the below)\n\n  * ILD as diagnosed and managed by a pulmonologist\n  * ILD based on diagnostic imaging criteria and abnormal DLCO\n  * ILD as a result of connective tissue diseases (e.g., polymyositis\u002Fdermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, mixed connective tissue disease)\n* ECOG performance status of 0 - 3\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Previous thoracic radiation\n* History of pneumonectomy\n* Major surgical procedure (e.g. intra-cranial, intra-thoracic, intra-abdominal, or intra-pelvic) within 28 days prior to enrollment.\n* Severe concurrent illness that may preclude timely completion of thoracic radiation or study procedures\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n* ILD exacerbation requiring hospitalization in the last 30 days\n* Poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential unless they are willing to employ a highly effective non-estrogen based contraception from screening to 30 days after the last dose of BIO 300 or to abstain from sexual intercourse during these time periods.\n\n  1. Effective method of non-estrogen-based contraception: condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill\n  2. Women who have been off estrogen contraceptives for a minimum 5 days prior to the first scheduled day of study intervention dosing are eligible.\n* Concomitant medications:\n\n  1. Any investigational anticancer therapy.\n  2. Planned concurrent chemotherapy or immunotherapy\n  3. Biologic drugs targeting the immune system (e.g. TNFα blockers, anakinra, rituximab, abatacept, tocilizumab) planned to be use concurrently with BIO 300",{"count":53,"type":21},25,[55],"PHASE2","The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).",[58,59,60,61,27,28,62,63],"NSCLC","NSCLC, Stage I","NSCLC Stage II","Non Small Cell Lung Cancer","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[61,65,66,58,67,60,62,63,68,69],"Non Small Cell Lung Cancer Stage I","Non Small Cell Lung Cancer Stage II","NSCLC Stage I","Memorial Sloan Kettering Cancer Center","25-310","RECRUITING","2026-03-02",{"date":73,"type":36},"2026-03-03",{"date":75,"type":36},"2026-01-06",{"date":77,"type":21},"2029-01-06",{"name":68,"class":43},7,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100625854","phase-2-a-study-of-trastuzumab-deruxtecan-in-people-with-non-small-cell-lung-cancer-100625854","NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients With Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES)","Inclusion Criteria:\n\nPatients must meet the following criteria for study entry:\n\nNeoadjuvant Therapy\n\n* Signed informed consent form\n* Age ≥18 years\n* Able to comply with the study protocol, in the investigator's judgment\n* Pathologically documented NSCLC\n\n  o Stage II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion), NSCLC (on the basis of the 8th edition of the AJCC NSCLC staging system)\n* Note: Patients may be enrolled on the basis of clinical stage, but documentation of nodal involvement by invasive mediastinal staging (e.g., endobronchial ultrasound or mediastinoscopy) is strongly encouraged\n* Molecular testing results on tissue and\u002For cfDNA from a CLIA-certified laboratory showing presence of a mutation or amplification (defined as ≥ 4 copies) of HER2. (See Appendix C for a list of known activating HER2 mutations in NSCLC. This is not intended to be a comprehensive list. The presence of any activating HER2 mutation is suitable.)of HER2including via Foundation Medicine testing on the LCMC4 LEADER protocol.\n* Molecular testing results used for patient eligibility should be obtained from a recent tumor biopsy (up to 6 months before enrollment). Alternatively, molecular testing results used to determine patient eligibility could have been obtained from a recent blood sample (up to 3 months before enrollment)\\]\n* Measurable disease as defined by RECIST v1.1 (exceptions may be made in cases of PERCIST-measurable disease \\[e.g., T0N2 cancer otherwise appropriate for induction therapy\\])\n* NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground-glass-opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured on the basis of the solid component only, exclusive of the ground-glass-opacity component\n* Evaluated by the attending surgeon before study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and to verify that the patient is medically operable\n* Adequate pulmonary function to be eligible for surgical resection with curative intent\n\n  * Pulmonary function tests (PFTs) must be performed at screening and before surgery,in accordance with the preoperative calendar of events, and should include lung volumes, spirometry, and diffusion capacity\n  * Abnormal PFT results may be further evaluated with quantitative ventilation or perfusion scanning or cardiopulmonary exercise testing, at the discretion of the surgeon\n  * Postoperative percent predicted forced expiratory volume in 1 second and diffusion capacity must be ≥40% and\u002For preoperative maximal oxygen consumption (VO2 max) must be \\>15 mL\u002Fkg\u002Fmin\n  * It is acceptable to have the screening PFTs performed within 4 months of Cycle 1, Day 1, but they must be repeated before Cycle 1, Day 1, if clinically indicated\n  * The postinduction and preoperative PFTs must be performed at least 2 weeks after Cycle 2, Day 1\n* Echocardiogram demonstrating left ventricular ejection fraction (LVEF) ≥50% within 28 days before enrollment. If clinically indicated, patients with underlying ischemic or valvular heart disease should be evaluated preoperatively by a cardiologist\n* ECOG Performance Status of 0 or 1\n* Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 14 days before the first dose of study treatment:\n\n  * Absolute neutrophil count ≥1500\u002FuL (granulocyte-colony stimulating factor administration is not allowed within 1 week before Cycle 1, Day 1)\n  * Platelet count ≥100,000\u002FuL (platelet transfusion is not allowed within 1 week before Cycle 1, Day 1)\n  * International normalized ratio or prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤1.5 × the upper limit of normal (ULN)\n  * Hemoglobin ≥9.0 g\u002FdL\n  * AST and ALT ≤3 × ULN\n  * Serum bilirubin ≤1.5 × ULN (up to 3 × ULN for patients with Gilbert syndrome)\n  * Creatinine clearance ≥30 mL\u002Fmin (as calculated using the Cockcroft-Gault equation)\n  * Serum albumin ≥2.5 g\u002FdL\n* Male and female participants of reproductive or childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4.5 months after the last dose of the study drug. Methods considered to be highly effective forms of contraception include:\n\n  o Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:\n* Oral\n* Intravaginal\n* Transdermal\n\n  o Progestogen-only hormonal contraception associated with inhibition of ovulation:\n* Oral\n* Injectable\n* Implantable\n\n  * Intrauterine device\n  * Intrauterine hormone-releasing system\n  * Bilateral tubal occlusion\n  * Vasectomized partner\n  * Complete sexual abstinence, defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 4.5 months after the last dose of the study drug. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.\n  * Women of nonchildbearing potential, defined as premenopausal women with a documented tubal ligation or hysterectomy, or postmenopausal women, defined as those with 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone \\>40 mIU\u002FmL and estradiol \\\u003C40 pg\u002FmL \\[\\\u003C147 pmol\u002FL\\] is confirmatory). Women on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of childbearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. After confirmation of their postmenopausal status, they can resume use of HRT during the study without the use of a contraceptive method\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period and for at least 4.5 months after the final administration of the study drug. Preservation of sperm should be considered before enrollment in this trial\n* Female participants must not donate or retrieve for their own use ova from the time of randomization or enrollment and throughout the study treatment period and for at least 7 months after the final administration of the study drug\n* Participants should be willing and able to comply with protocol visits and procedures\n\nAdjuvant Therapy Adjuvant systemic therapy (i.e., platinum-based chemotherapy and\u002For immunotherapy) may be given to patients at the discretion of the treating physician.\n\nExclusion Criteria:\n\n* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or stage IIIB by virtue of N3 disease\n* Patients who on initial assessment by treating thoracic surgeon, appear to require a total pneumonectomy to achieve a complete resection are ineligible for study enrollment\n* Any previous therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 3 years\n* Previous lung cancer in remission for \\\u003C3 years, with the exception of minimally invasive adenocarcinoma or incidental typical carcinoid tumors\n* History of (noninfectious) ILD or pneumonitis that required steroids or current ILD or pneumonitis or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening\n* Lung-specific intercurrent clinically significant illnesses including but not limited to any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of study enrollment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, pleural effusion)\n* Any autoimmune, connective tissue, or inflammatory disorders (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis) where there is documentation or suspicion of pulmonary involvement, at the time of screening. Full details of the disorder should be recorded in the eCRF for patients who are included in the study\n* Previous pneumonectomy (complete)\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals\n* Active primary immunodeficiency, known uncontrolled active HIV infection, or active hepatitis B or C infection, such as those with serologic evidence of viral infection within 28 days of Cycle, 1 Day 1. Participants with past or resolved hepatitis B virus infection who are anti-HBc positive (+) are eligible only if they are HBsAg negative (-)\n* Corrected QT interval prolongation to \\>470 msec (women) or \\>450 msec (men) on the basis of the average of the screening triplicate 12-lead electrocardiogram (ECG)\n* Receipt of live, attenuated vaccine (mRNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days before the first dose of T-DXd.\n\nNote: Patients, if enrolled, should not receive live vaccine during the study and for up to 30 days after the last dose of the study drug\n\n* Known allergy or hypersensitivity to the study treatment or any of the study drug excipients\n* History of severe hypersensitivity reactions to other monoclonal antibodies\n* Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study,in the opinion of the investigator\n* Major surgical procedure within 28 days before Cycle 1, Day 1\n* Malignancies other than the disease under study within 3 years before Cycle 1, Day 1, with the exception of patients with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, non-muscle invasive bladder cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or patients undergoing active surveillance per standard-of-care management (e.g., Rai stage 0 chronic lymphocytic leukemia, prostate cancer with Gleason score ≤6, and prostate-specific antigen \\[≤10 ng\u002FmL\\])\n* Treatment with an investigational agent for any condition within 4 weeks before Cycle 1, Day 1 (or within 5 half-lives of the investigational product, whichever is longer)\n* Medical history of myocardial infarction, symptomatic congestive heart failure (CHF; New York Heart Association class II-IV), unstable angina, or serious cardiac arrhythmia\n* Social, familial, or geographical factors that would interfere with study participation or follow-up\n* Concomitant medical condition that would increase the risk of toxicity, in the opinion of the investigator\n* Pregnant or lactating or intending to become pregnant during the study o Women of childbearing potential must have a negative serum pregnancy test result within 7 days before initiation of treatment",{"count":88,"type":21},14,[55],"The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.",[92,28,93,94],"Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer Stage IIIA","Non-Small Cell Lung Cancer Stage IIIB",[92,96,93,97,68,98],"Non-Small Cell Lung Cancer Stage II","Non-Small Cell Lung Cancer IIIB","25-110","2026-02-17",{"date":101,"type":36},"2026-02-23",{"date":103,"type":36},"2026-02-13",{"date":105,"type":21},"2027-02-13",{"name":68,"class":43},10,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100407442","phase-2-adjuvant-ctdna-adapted-personalized-treatment-in-early-stage-nsclc-adapt-e-100407442","NCT04585477","Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","Inclusion Criteria\n\n1. Pathologically (histologically or cytologically proven) NSCLC. Tumors with any component of small cell lung cancer are not allowed.\n\n   Adenocarcinoma patients must NOT be positive for EGFR Exon 19 deletion or L858R mutation, or ALK or ROS1 rearrangement.\n2. AJCC 8th edition clinical or pathological stage IA2 to IIIC or locoregionally recurrent disease. Stage IA1 tumors are excluded unless recurrent with radiographic solid component -or- pathologic invasive component of \\> 10 mm.\n3. Received curative intent therapy with surgery and\u002For radiation. Note: May have received chemotherapy.\n4. Completed all intended therapy (surgery, radiation, and\u002For chemotherapy) - AND- no more than 32 weeks has elapsed after the last day of this therapy.\n5. No known current radiographic or pathologic residual\u002Frecurrent disease (in the investigator's opinion) after completion of all intended therapy (for example, positive margins after surgery without adjuvant radiotherapy, or unequivocal radiographic evidence of residual or recurrent disease)\n6. Pre-treatment tumor tissue or tumor DNA sample is believed to be available for analysis\n7. Not received immunotherapy (PD-1, PD-L1, or CTLA-4 antibodies) or be intended to receive immunotherapy, apart from this study.\n8. Not received another systemic anti-cancer investigational product during the 4 weeks prior to enrollment.\n9. Aged 18 years or older\n10. ECOG Performance Status of 0 or 1 (Appendix B)\n11. Life expectancy ≥ 12 weeks\n12. Acceptable laboratory parameters:\n13. Absolute neutrophil count \\> 1.0 x 109\u002FL\n14. Platelets \\> 75 x 109\u002FL\n15. Hemoglobin ≥ 9.0 g\u002FdL\n16. Creatinine ≤ 1.5 x ULN; or Measured creatinine clearance (CL) \\>40 mL\u002Fmin; or Calculated creatinine CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976)\n17. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology) who will be allowed in consultation with their physician.\n18. AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN)\n19. Ability to understand and the willingness to sign the written IRB approved informed consent document.\n20. Women of childbearing potential or their male partner must agree to use a highly effective method of contraception from enrollment until 8 months after final study therapy. (see section 4.6.1)\n21. Body weight \\>30kg\n\nExclusion Criteria\n\n1. Involvement in the planning and\u002For conduct of the study\n2. History of Grade 3 or higher pneumonitis from prior radiation; patients with grade 2 radiation pneumonitis may be considered for enrollment with permission from the Protocol Director or Co-Director.\n3. History of another primary malignancy and currently undergoing active treatment Exception: May participate if receiving adjuvant endocrine therapy for breast or prostate cancer.\n4. Expected to require ongoing chronic treatment with systemic immunosuppressive medication after enrollment.\n\n   Exceptions: intranasal, inhaled, or topical corticosteroids or systemic corticosteroids at physiological doses, not to exceed 10 mg\u002Fday of prednisone equivalent\n5. Any unresolved toxicity CTCAE \\> Grade 2 from prior therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n\n   * Subjects with Grade \\> 2 neuropathy will be evaluated on a case by case basis after consultation with the Protocol Director \u002F Principal Investigator\n   * Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with durvalumab may be included (ie, hearing loss) with permission from the Protocol Director \u002F Co-Director.\n6. Active or prior documented autoimmune or inflammatory disorders which could limit the subjects ability to receive durvalumab on the study (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis; Graves' disease; rheumatoid arthritis; hypophysitis; uveitis; etc\\]). The following may be taken in to considerations as exceptions to this criterion:\n\n   1. Vitiligo or alopecia\n   2. Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n   3. Chronic skin condition not requiring systemic therapy\n   4. Those without active disease in the last 5 years may be included with permission from the Protocol Director \u002F Co-Director.\n   5. Celiac disease controlled by diet alone\n7. History of primary immunodeficiency\n8. History of organ transplant requiring therapeutic immunosuppression\n9. Active infection including:\n\n   * Grade 3 or higher clinically significant infection\n   * Active known Hepatitis B \\[known positive results for HBV surface antigen (HBsAg) within 2 months prior to enrollment\\]. EXCEPTION: Subjects with a past or resolved HBV infection, defined as the presence of hepatitis B core antibody (anti HBc) and absence of HBsAg are eligible.\n   * Active known Hepatitis C (HCV) EXCEPTION: Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA\n   * Active known tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n   * Active known HIV: tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies)\n10. Receipt of live (growth\u002Freplication competent) attenuated vaccine within 30 days prior to enrollment.\n\n    Note: Subjects, if enrolled, should not receive live vaccine while receiving the investigational product (IP), and through 30 days after the last dose of IP.\n11. Uncontrolled intercurrent illness, including but not limited to clinically significant:\n\n    * Symptomatic congestive heart failure\n    * Uncontrolled hypertension\n    * Unstable angina pectoris\n    * Cardiac arrhythmia\n    * Interstitial lung disease (presence of radiation pneumonitis on CT scan is allowed)\n    * Serious chronic gastrointestinal conditions associated with diarrhea\n    * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.\n12. Female subjects who are pregnant or breast feeding.\n13. Any other medical condition that, in the investigator's opinion, makes the subject unsuitable for enrollment and study procedures.\n14. Female subjects who are pregnant or breast-feeding; or subjects of reproductive potential of any gender who are not employing or who do not agree to employ an effective method of birth control (see Section 4.7) prior to trial enrollment.",true,{"count":116,"type":21},80,[55],"In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.",[30,27,28,120],"Non-small Cell Lung Cancer Stage III","2026-02-07",{"date":123,"type":36},"2026-02-10",{"date":125,"type":36},"2021-04-08",{"date":127,"type":21},"2026-12-30",{"name":129,"class":43},"Stanford University",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":130},"100256852","clinical-research-platform-into-molecular-testing-treatment-and-outcome-of-non-small-cell-lung-carcinoma-patients-100256852","NCT02622581","Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients","CRISP","Inclusion Criteria:\n\nPatients who meet all of the following criteria are eligible for the project:\n\n* Age ≥ 18 years\n* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments\n\nMain project (Metatstatic NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\"\n* Stage IV, or stage IIIB\u002FC (UICC8) if patient is ineligible for curative surgery and\u002For radiochemotherapy\n* Systemic therapy or best supportive care\n\nSatellite Stage I\u002FII\u002FIII (NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Stage I, Stage II, stage IIIA, or stage IIIB\u002FC (UICC8)\n* Systemic (chemo)therapy and\u002For radiation therapy and\u002For surgery or best supportive care\n\nSatellite SCLC\n\n* Confirmed Small cell lung cancer (SCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Systemic (chemo)therapy and\u002For radiation therapy and\u002For surgery or best supportive care\n\nExclusion Criteria:\n\nnone",{"count":139,"type":21},12400,"3 Years","OBSERVATIONAL","Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany",[144,145,28,146,147,27],"Metastatic Non-small Cell Lung Cancer (NSCLC)","Non-small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer Stage III","Small-cell Lung Cancer","2025-02-14",{"date":150,"type":36},"2025-02-18",{"date":152,"type":36},"2015-12",{"date":154,"type":21},"2027-12",{"name":156,"class":43},"AIO-Studien-gGmbH"]